Overview

A Study of Bimatoprost 0.01% in the Clinical Setting

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
0
Participant gender:
All
Summary
This is a study of bimatoprost 0.01% (LUMIGANĀ® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Criteria
Inclusion Criteria:

- Diagnosis of primary open-angle glaucoma or ocular hypertension

- Determined by the treating physician to require treatment with bimatoprost 0.01%.

Exclusion Criteria:

- Previous use of LumiganĀ® 0.01%